Shanghai Haohai Biological Technology 

¥28.00
0
-¥0.50-1.75% 07:00 Today

Statistics

Day High
28.86
Day Low
27.9
52W High
51.84
52W Low
27.6
Volume
476,596
Avg. Volume
516,315
Mkt Cap
7.02B
P/E Ratio
28.67
Dividend Yield
2.91%
Dividend
0.82

Upcoming

Dividends

2.91%Dividend Yield
Oct 2026
¥0.25
Jul 2026
¥0.59
Oct 2025
¥0.40
Jul 2025
¥0.60
Oct 2024
¥0.40
10Y Growth
11.22%
5Y Growth
17.69%
3Y Growth
45.85%
1Y Growth
-10.63%

Earnings

Oct 23Expected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q3 2026
0.03
0.04
0.04
0.05
Expected EPS
N/A
Actual EPS
0.029245354313999997

Financials

10.26%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
2.45BRevenue
251.01MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

Shanghai Haohai Biological Technology Co., Ltd. is a global enterprise dedicated to the research, development, manufacturing, and commercialization of biomedical materials. Its operations span Mainland China, the United States, the United Kingdom, and various other international regions. A comprehensive product portfolio addresses several key medical disciplines. Within ophthalmology, offerings include intraocular lenses, ophthalmic viscoelastic devices, orthokeratology and phakic refractive lenses, eye drops, injectors, and surgical scalpels. Orthopedics products encompass sodium hyaluronate injections and medical chitosan. For wound repair, it manufactures recombinant human epidermal growth factor, effective in treating burn wounds, residual wounds, donor site post-traumatic wounds, and both fresh and chronic ulcerations. Additionally, the company develops anti-adhesion materials, including medical sodium hyaluronate gel and medical chitosan, as well as hemostatic solutions such as collagen sponges and porcine fibrin sealants. Beyond its therapeutic offerings, Shanghai Haohai maintains a significant presence in the medical aesthetics market. This segment features a range of hyaluronic acid (HA) dermal fillers: Matrifill, positioned as a first-generation mono-phase injectable HA gel; Janlane, a second-generation filler engineered for dynamic application; and Hyalumatrix, a third-generation product providing precise aesthetic embellishment. Its aesthetic portfolio is further complemented by radio frequency devices and laser equipment. Furthermore, the company actively engages in the research and development of biological engineering and pharmaceutical products, extending services such as technology transfer and consultation. It also conducts investment and trading operations. Established in 2007, the entity initially traded as Haohai Limited before officially adopting the name Shanghai Haohai Biological Technology Co., Ltd. in 2010. Its corporate headquarters are based in Shanghai, China.
Show More
CEO
Wu Jianying
Employees
2110
Country
China
ISIN
CNE100003NX4

Listings

0 Comments

Share your thoughts

FAQs

What is Shanghai Haohai Biological Technology stock price today?▼
The current price of 688366.SHG is ¥28.00 CNY — it has decreased by -1.75% in the past 24 hours. Watch Shanghai Haohai Biological Technology stock price performance more closely on the chart.
What is Shanghai Haohai Biological Technology stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Shanghai Stock Exchange exchange Shanghai Haohai Biological Technology stocks are traded under the ticker 688366.SHG.
Is Shanghai Haohai Biological Technology stock price growing?▼
688366.SHG stock has fallen by -4.73% compared to the previous week, the month change is a -6.07% fall, over the last year Shanghai Haohai Biological Technology has showed a -44.75% decrease.
What is Shanghai Haohai Biological Technology market cap?▼
Today Shanghai Haohai Biological Technology has the market capitalization of 7.02B
When is the next Shanghai Haohai Biological Technology earnings date?▼
Shanghai Haohai Biological Technology is going to release the next earnings report on March 22, 2027.
What were Shanghai Haohai Biological Technology earnings last quarter?▼
688366.SHG earnings for the last quarter are 0.22 CNY per share, whereas the estimation was N/A CNY resulting in a N/A surprise. The estimated earnings for the next quarter are N/A CNY per share.
What is Shanghai Haohai Biological Technology revenue for the last year?▼
Shanghai Haohai Biological Technology revenue for the last year amounts to 2.45B CNY.
What is Shanghai Haohai Biological Technology net income for the last year?▼
688366.SHG net income for the last year is 251.01M CNY.
Does Shanghai Haohai Biological Technology pay dividends?▼
Yes, 688366.SHG dividends are paid semi-annual. The last dividend per share was 0.25 . As of today, Dividend Yield (FWD)% is 2.91%.
How many employees does Shanghai Haohai Biological Technology have?▼
As of November 18, 2026, the company has 2,110 employees.
In which sector is Shanghai Haohai Biological Technology located?▼
Shanghai Haohai Biological Technology operates in the Health & Wellness sector.
When did Shanghai Haohai Biological Technology complete a stock split?▼
The last stock split for Shanghai Haohai Biological Technology was on June 20, 2024 with a ratio of 1.4:1.
Where is Shanghai Haohai Biological Technology headquartered?▼
Shanghai Haohai Biological Technology is headquartered in Shanghai, China.